Date: 2013-05-31
Type of information: Licensing agreement
Compound: EZH2 Y641 mutation biomarker
Company: Qiagen (The Netherlands) BC Cancer Agency (Canada)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease:
Details: * On May 31, 2013, Qiagen has entered into an exclusive license option with the BC Cancer Agency, based in Vancouver, British Columbia, Canada, for the EZH2 Y641 mutation biomarker that could serve as a companion diagnostic test for routine selection of patients who could benefit from EZH2 targeted therapies that are currently under development by major pharmaceutical companies.
Financial terms:
Latest news:
